Business context and reporting period
Geron Corporation’s Form 10-K covers the fiscal year ended December 31, 2011; quarterly figures below refer to the fourth quarter. Geron is a clinical-stage biopharmaceutical company with no therapeutic products for sale. Its oncology pipeline comprised four Phase 2 trials of imetelstat and two Phase 2 trials of GRN1005. In November 2011, the company discontinued further development of its stem-cell programs to focus on oncology.
Financial performance and liquidity
Amounts are in U.S. dollars; financial statement amounts are shown in millions unless noted.
| Metric | FY 2011 | FY 2010 |
|---|---|---|
| Revenue | $2.438 | $3.563 |
| Research and development expense | $69.316 | $61.687 |
| General and administrative expense | $23.789 | $18.043 |
| Operating loss | $(96.116) | $(111.167) |
| Net loss | $(96.853) | $(111.377) |
| Net loss per share | $(0.78) | $(1.14) |
| Cash used in operating activities | $(62.392) | $(44.292) |
Revenue consisted mainly of license fees, royalties and collaboration payments; Geron reported no therapeutic-product sales. Operating and net losses continued, and the company has incurred operating losses since inception. No gross margin metric is meaningful for the reported business mix.
At year-end, cash, restricted cash, cash equivalents and marketable securities totaled $154.239 million, down from $221.274 million. This included $16.105 million of cash and cash equivalents, $0.793 million of restricted cash and $137.341 million of marketable securities. Working capital was $112.181 million, versus $154.168 million in 2010. Total assets were $160.047 million and stockholders’ equity was $146.603 million. The CIRM loan was fully repaid in November; no debt remained at year-end. Approximately $0.5 million remained available under the equipment financing facility.
Fourth-quarter comparison
| Metric | Q4 2011 | Q4 2010 |
|---|---|---|
| Revenue | $0.251 million | $1.098 million |
| Operating expenses | $30.659 million | $60.709 million |
| Net loss | $(31.854) million | $(59.362) million |
| Net loss per share | $(0.25) | $(0.59) |
Material changes versus prior period
- Annual revenue declined about 32% from 2010, including lower collaboration revenue after the GE Healthcare alliance concluded in June 2011.
- R&D expense increased about 12%, primarily reflecting imetelstat trial activity and clinical drug-product manufacturing. Management expected R&D expense to decrease following the stem-cell program exit.
- 2011 net loss was lower than 2010 largely because 2010 included $35.0 million of acquired in-process R&D expense for the Angiochem license. The 2011 results included $5.449 million of restructuring charges and a $1.664 million debt-extinguishment charge.
- Cash used in operations rose to $62.392 million from $44.292 million. Year-end liquid resources fell by $67.035 million.
- The restructuring eliminated 66 positions, approximately 38% of the workforce. Geron reported 111 full-time employees as of February 1, 2012, plus 14 employees continuing transition work.
Outlook, risks and unusual items
- Management estimated existing capital resources, interest income and equipment financing availability would fund the current level of operations for at least 12 months, while warning that future capital needs would be substantial and additional financing might be required.
- Geron expected top-line results from all four imetelstat Phase 2 trials by the end of 2012, subject to sufficient progression events in the randomized breast-cancer and NSCLC trials. It expected GRN1005 Phase 2 top-line data by the end of Q2 2013. The trials were not powered to establish statistical significance; reported objectives include efficacy estimates and trends.
- Enrollment in the imetelstat essential-thrombocythemia and multiple-myeloma trials was slower than expected; GRN1005 trials had aggressive enrollment goals. The filing notes dose-limiting blood-count toxicities for imetelstat and neutropenia for GRN1005, and describes GRN1005 clinical evidence as preliminary.
- Key risks include clinical failure or delay, regulatory uncertainty, manufacturing scale, cost and quality challenges, reliance on third-party suppliers and service providers, patent disputes, competition and potential need for dilutive financing. Geron had a single supplier for GRN1005 bulk drug substance and no long-term supply agreements.
- The company intended to divest its stem-cell assets in 2012 but provided no assured value or transaction proceeds. It estimated about $4.4 million of restructuring cash expenditures, with approximately $3.7 million of termination benefits expected in 2012; additional exit charges could arise.
- Auditors issued unqualified opinions on the financial statements and internal controls. Management also concluded disclosure controls and internal control over financial reporting were effective as of year-end.
Important facts for investors to verify
- Whether the stated clinical-data timelines were met, and the full efficacy and safety results—including subgroup findings and the limitations of the Phase 2 designs.
- Actual quarterly cash burn, remaining runway and financing plans relative to the company’s estimate of at least 12 months of current-level operations.
- Progress, timing and net proceeds, if any, from the planned stem-cell asset divestiture, alongside any remaining wind-down costs.
- Whether manufacturing capacity, product quality and supply continuity can support later-stage trials, particularly for GRN1005.
- Potential dilution and share overhang: 131.443 million common shares were outstanding at year-end, with additional shares reserved for options, awards and warrants.